Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Emergent Biosolutions To Acquire Trubion
by Ann M. Thayer
August 23, 2010
| A version of this story appeared in
Volume 88, Issue 34
Emergent BioSolutions, a developer of vaccines and other agents against infectious diseases, will acquire Trubion Pharmaceuticals in a deal worth up to $136 million. Emergent will pay $97 million up front and as much as $39 million in milestones. Trubion has two protein-based oncology and autoimmunity drug candidates in clinical testing and others in preclinical development. Rockville, Md.-based Emergent will use Trubion’s Seattle research site for therapeutics-focused product development.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X